Zobrazeno 1 - 10
of 407
pro vyhledávání: '"Taroh, Satoh"'
Autor:
Hiroki Osumi, Eiji Shinozaki, Yoshiaki Nakamura, Taito Esaki, Hisateru Yasui, Hiroya Taniguchi, Hironaga Satake, Yu Sunakawa, Yoshito Komatsu, Yoshinori Kagawa, Tadamichi Denda, Manabu Shiozawa, Taroh Satoh, Tomohiro Nishina, Masahiro Goto, Naoki Takahashi, Takeshi Kato, Hideaki Bando, Kensei Yamaguchi, Takayuki Yoshino
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-11 (2024)
Abstract “NeoRAS WT” refers to the loss of RAS mutations (MTs) following first-line treatment in metastatic colorectal cancer (mCRC). We evaluate the incidence and clinicopathological characteristics of NeoRAS WT mCRC using next-generation sequen
Externí odkaz:
https://doaj.org/article/32159db2ff3a4f6f8eaee8f39adf3f96
Autor:
Chihiro Sato, Hisato Kawakami, Ryo Tanaka, Hironaga Satake, Kentaro Inoue, Yutaka Kimura, Junya Fujita, Ryohei Kawabata, Yasutaka Chiba, Taroh Satoh, Kazuhiko Nakagawa
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-10 (2023)
Abstract Adjuvant S-1 monotherapy is the standard of care for stage II gastric cancer (GC) after curative resection in Japan, but its efficacy for microsatellite instability–high (MSI-H) tumors has remained unknown. Among a multi-institutional coho
Externí odkaz:
https://doaj.org/article/530edf29753342e095c74eb7211e943c
Autor:
Takehiro Noda, Hidekazu Takahashi, Mitsuyoshi Tei, Naohiro Nishida, Taishi Hata, Yutaka Takeda, Masayuki Ohue, Hiroshi Wada, Tsunekazu Mizushima, Tadafumi Asaoka, Mamoru Uemura, Shogo Kobayashi, Kohei Murata, Taroh Satoh, Yuichiro Doki, Hidetoshi Eguchi, the Clinical Study Group of Osaka University (CSGO), Colorectal Group, and Hepato‐Biliary‐Pancreatic Group
Publikováno v:
Annals of Gastroenterological Surgery, Vol 7, Iss 3, Pp 479-490 (2023)
Abstract Aims Risk‐scoring systems for colorectal liver metastasis (CRLM) after hepatectomy allow prognoses to be predicted preoperatively. We investigated the clinical outcomes of neoadjuvant chemotherapy for resectable CRLM according to patient r
Externí odkaz:
https://doaj.org/article/825199e8c01f430294199755f34d14a5
Autor:
Chiaki Inagaki, Hisato Kawakami, Daichi Maeda, Daisuke Sakai, Shinya Urakawa, Kentaro Nishida, Toshihiro Kudo, Yuichiro Doki, Hidetoshi Eguchi, Hisashi Wada, Taroh Satoh
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-12 (2023)
Abstract To assess the potential clinical utility of cell-free DNA (cfDNA)-based biomarkers for identifying gastric cancer (GC) patients who benefit from nivolumab. From 31 GC patients treated with nivolumab monotherapy (240 mg/body, Bi-weekly) in 3r
Externí odkaz:
https://doaj.org/article/ecf4d4d29edc41ecacfb02945d3c66d1
Autor:
Hiromichi Sato, Sikun Meng, Tomoaki Hara, Yoshiko Tsuji, Yasuko Arao, Kazuki Sasaki, Shogo Kobayashi, Eric di Luccio, Takaaki Hirotsu, Taroh Satoh, Yuichiro Doki, Hidetoshi Eguchi, Hideshi Ishii
Publikováno v:
Biomedicines, Vol 12, Iss 6, p 1342 (2024)
Gastrointestinal cancers, which include a variety of esophageal and colorectal malignancies, present a global health challenge and require effective treatment strategies. In the evolving field of cancer immunotherapy, tissue-resident memory T cells (
Externí odkaz:
https://doaj.org/article/0ee6a72de09048599fcc421fc0d0280f
Autor:
Takeshi Kato, Toshihiro Kudo, Yoshinori Kagawa, Kohei Murata, Hirofumi Ota, Shingo Noura, Junichi Hasegawa, Hiroshi Tamagawa, Katsuya Ohta, Masakazu Ikenaga, Susumu Miyazaki, Takamichi Komori, Mamoru Uemura, Junichi Nishimura, Taishi Hata, Chu Matsuda, Taroh Satoh, Tsunekazu Mizushima, Yuko Ohno, Hirofumi Yamamoto, Yuichiro Doki, Hidetoshi Eguchi
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-8 (2023)
Abstract Regorafenib has shown significant survival benefit as a salvage therapy for colorectal cancer; however, its starting dose has been controversial in recent studies. Therefore, we conducted a prospective study on the efficacy and safety of the
Externí odkaz:
https://doaj.org/article/9bbabfbd9acf414bb4f4b4ff00be6559
Autor:
Chu Matsuda, Toshihiro Kudo, Yoshihiro Morimoto, Yoshinori Kagawa, Mitsuyoshi Tei, Yoshihito Ide, Norikatsu Miyoshi, Hidekazu Takahashi, Mamoru Uemura, Ichiro Takemasa, Taroh Satoh, Tsunekazu Mizushima, Kohei Murata, Yuichiro Doki, Hidetoshi Eguchi, Multicenter Clinical Study Group of Osaka, Colorectal Cancer Treatment Group (MSCSGO)
Publikováno v:
Annals of Gastroenterological Surgery, Vol 7, Iss 1, Pp 81-90 (2023)
Abstract Purpose Addition of perioperative multi‐agent chemotherapy to the treatment strategy for locally advanced rectal cancer (LARC) may be a promising option. We conducted a phase II study to evaluate the safety and efficacy of capecitabine com
Externí odkaz:
https://doaj.org/article/3eb8581c6edc4b6cb42324eb3f36b42d
Autor:
Saori Mishima, Yoshiaki Nakamura, Hanna Tukachinsky, Hiroya Taniguchi, Shigenori Kadowaki, Ken Kato, Eiji Oki, Taroh Satoh, Daisuke Aoki, Kentaro Yamazaki, Taito Esaki, Makoto Ueno, Tomohiro Nishina, Yu Sunakawa, Tadamichi Denda, Hideaki Bando, Naomi Kuramoto, Satoshi Horasawa, Hikaru Abutani, Jessica K. Lee, Russell W. Madison, Geoffrey R. Oxnard, Takayuki Yoshino
Publikováno v:
The Journal of Liquid Biopsy, Vol 1, Iss , Pp 100003- (2023)
Background: The tumor mutational burden (TMB) is a genomic biomarker associated with the benefits from immune checkpoint inhibitors (ICIs) cancer therapy. An elevated blood TMB (bTMB) in circulating tumor DNA (ctDNA) represents a compelling non-invas
Externí odkaz:
https://doaj.org/article/319817859d4c4310b633530ef5835093
Autor:
Shunji Endo, Tetsuji Terazawa, Masahiro Goto, Ryo Tanaka, Takeshi Kato, Kazumasa Fujitani, Hisato Kawakami, Daisuke Sakai, Yukinori Kurokawa, Toshimasa Tsujinaka, Toshio Shimokawa, Taroh Satoh
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-8 (2022)
Abstract Background Large type 3 and type 4 gastric cancers have extremely poor prognoses. To address this, neoadjuvant chemotherapy may be a promising approach. The phase III JCOG0501 study, conducted to confirm the superiority of neoadjuvant S-1 pl
Externí odkaz:
https://doaj.org/article/64021a2d99e14bdca8abdc549a131c7c
Autor:
Toshifumi Yamaguchi, Hisato Kawakami, Daisuke Sakai, Yukinori Kurokawa, Toshio Shimokawa, Masahiro Goto, Taroh Satoh
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-6 (2022)
Abstract Background Although docetaxel plus S-1 adjuvant chemotherapy after gastrectomy with D2 lymphadenectomy has been a standard of treatment for stage III gastric cancer, there is no established chemotherapy for patients with recurrence during or
Externí odkaz:
https://doaj.org/article/baaa9aef03d34117ae82f3ae1201ee5a